Oct 16, 2024
GSK files lawsuit against Moderna alleging unauthorized use of their COVID-19 mRNA vaccine patents. (Source)
Oct 03, 2024
New Scientific Study: A multivalent mRNA-LNP vaccine offers protection against Clostridioides difficile infection. (Source)
Aug 16, 2024
Pfizer and BioNTech‘s combined COVID-19 and influenza vaccine falls short of its primary goal in Phase 3 clinical trials, demonstrating limited effectiveness against both influenza A and B strains. (Source)
July 03, 2024
GSK acquires CureVac’s mRNA vaccine assets for influenza and COVID-19, paying $430 million upfront and an additional $1.13 billion in milestone payments. (Source)
July 02, 2024
Moderna, Inc. has been granted a $176 million award through the RRPV to expedite the development of mRNA-based pandemic influenza vaccines. (Source)
